Comparison of bluebird bio Inc. (BLUE) and Pulmatrix Inc. (NASDAQ:PULM)

This is a contrast between bluebird bio Inc. (NASDAQ:BLUE) and Pulmatrix Inc. (NASDAQ:PULM) based on their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
bluebird bio Inc. 39.50M 187.77 523.83M -8.19 0.00
Pulmatrix Inc. N/A 33.36 20.75M -0.69 0.00

Table 1 demonstrates bluebird bio Inc. and Pulmatrix Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 has bluebird bio Inc. and Pulmatrix Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
bluebird bio Inc. -1,326.15% -31.5% -26.6%
Pulmatrix Inc. 0.00% -176.2% -124.7%

Volatility & Risk

A 2.44 beta means bluebird bio Inc.’s volatility is 144.00% more than Standard & Poor’s 500’s volatility. From a competition point of view, Pulmatrix Inc. has a 2.27 beta which is 127.00% more volatile compared to Standard & Poor’s 500.


The Current Ratio and Quick Ratio of bluebird bio Inc. are 13.1 and 13.1 respectively. Its competitor Pulmatrix Inc.’s Current Ratio is 1.3 and its Quick Ratio is 1.3. bluebird bio Inc. can pay off short and long-term obligations better than Pulmatrix Inc.

Analyst Ratings

In next table is given bluebird bio Inc. and Pulmatrix Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
bluebird bio Inc. 0 2 5 2.71
Pulmatrix Inc. 0 0 0 0.00

bluebird bio Inc. has a consensus price target of $147.83, and a 9.00% upside potential.

Insider & Institutional Ownership

bluebird bio Inc. and Pulmatrix Inc. has shares owned by institutional investors as follows: 0% and 20.7%. Insiders owned 0.3% of bluebird bio Inc. shares. Competitively, 0.76% are Pulmatrix Inc.’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
bluebird bio Inc. -16.88% -23.58% -30.98% -43.22% -39.16% -42.64%
Pulmatrix Inc. 4.86% -4.59% -6.24% -35.93% -75.36% -72.74%

For the past year bluebird bio Inc. was less bearish than Pulmatrix Inc.


bluebird bio Inc. beats on 7 of the 10 factors Pulmatrix Inc.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The companyÂ’s proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis (IPF). It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease. The company has an alliance with Celdara to develop an inhaled biologic to treat IPF. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.